- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03308097
A Mobile Intervention to Improve Uptake of PrEP for Southern Black MSM (MobilePrEP)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Mississippi
-
Jackson, Mississippi, United States, 39216
- University of Mississippi Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- English speaking
- Black MSM
- Eligible for PrEP
- Visit STI/HIV testing clinics at University of Mississippi Medical Center
- Able to give consent/assent and not impaired by cognitive or medical limitations as per clinical assessment
Exclusion Criteria:
- Involved in another PrEP or HIV prevention related study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: PrEP Mobile Messaging Intervention
Participants from the STI/HIV testing clinic will receive Enhanced Standard of Care (described below) plus texted messages with the intervention content and follow-up questions over the next 4 weeks on their cell phones.
Participants will receive approximately 8-16 interactive text messages with links to web content.
Texts will be sent twice a week over the next 4 weeks.
Participants will return for 2 more appointments over the next couple of months to fill out questionnaires.
|
See group description
|
|
Active Comparator: Enhanced Standard of Care
As part of the enhanced standard of care, participants seen in the STI/HIV testing clinic are given feedback regarding PrEP eligibility and current risk behaviors.
Participants are also given an informational handout about PrEP, shown a brief video, and given contact information for the PrEP Clinic Care Coordinator.
Participants will return for 2 more visits over the next couple months to fill out questionnaires.
|
See group description
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of PrEP Services Appointments Attended-Full Sample
Time Frame: 16 weeks
|
With participant consent, staff at the STI/HIV testing clinic will abstract from the electronic medical record any PrEP Services Appointment, and any PrEP related care.
|
16 weeks
|
|
Number of PrEP Services Appointments Attended- Restricted Sample
Time Frame: 16 weeks
|
With participant consent, staff at the STI/HIV testing clinic will abstract from the electronic medical record any PrEP Services Appointment, and any PrEP related care. Restricted Sample is only those who did not receive a PrEP prescription the same day as enrollment. |
16 weeks
|
|
Number of Participants Who Received a PrEP Prescription-Full Sample
Time Frame: 16 weeks
|
Staff at the testing clinic will abstract any prescription written for PrEP at 16 weeks for the participant.
|
16 weeks
|
|
Number of Participants Who Received a PrEP Prescription-Restricted Sample
Time Frame: 16 weeks
|
Staff at the testing clinic will abstract any prescription written for PrEP at 16 weeks for the participant. Restricted sample is those who did not receive a PrEP prescription the same day as enrollment. |
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in PrEP Knowledge-Full Sample
Time Frame: Baseline, 16 weeks
|
Change in participants score on the PrEP Knowledge Questionnaire between baseline and 16 weeks follow-up.
Scores can range from 0-3, with higher scores indicating greater PrEP knowledge.
|
Baseline, 16 weeks
|
|
Change in PrEP Knowledge-Restricted Sample
Time Frame: Baseline, 16 weeks
|
Change in participants score on the PrEP Knowledge Questionnaire between baseline and 16 weeks follow-up. Scores can range from 0-3, with higher scores indicating greater PrEP knowledge. Restricted sample is those who did not receive a PrEP prescription the same day as enrollment. |
Baseline, 16 weeks
|
|
Change in Social Motivational Readiness for PrEP Care-Full Sample
Time Frame: Baseline, 16 weeks
|
Change in participants' score on the IMB PrEP Motivation Scale (to assess personal and social motivations for PrEP use) from baseline to16 weeks follow-up.
Scores can range from 8 - 32, with higher scores indicating greater motivation.
|
Baseline, 16 weeks
|
|
Change in Social Motivational Readiness for PrEP Care-Restricted Sample
Time Frame: Baseline, 16 weeks
|
Change in participants' score on the IMB PrEP Motivation Scale (to assess personal and social motivations for PrEP use) from baseline to16 weeks follow-up. Scores can range from 8 - 32, with higher scores indicating greater motivation. Restricted sample is those who did not receive a PrEP prescription the same day as enrollment. |
Baseline, 16 weeks
|
|
Change in PrEP Self-efficacy-Full Sample
Time Frame: Baseline, 16 weeks
|
Change in participants' score on the IMB PrEP Behavioral Skills Scale between baseline and 16 weeks, which assesses self-efficacy for taking PrEP as prescribed and assesses self-efficacy for PrEP related medical appointments.
Scores can range from 7 - 28, with higher scores indicating greater self-efficacy.
|
Baseline, 16 weeks
|
|
Change in PrEP Self-efficacy-Restricted Sample
Time Frame: Baseline, 16 weeks
|
Change in participants' score on the IMB PrEP Behavioral Skills Scale between baseline and 16 weeks, which assesses self-efficacy for taking PrEP as prescribed and assesses self-efficacy for PrEP related medical appointments. Scores can range from 7 - 28, with higher scores indicating greater self-efficacy. Restricted sample is those who did not receive a PrEP prescription the same day as enrollment. |
Baseline, 16 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Larry K. Brown, M.D., Rhode Island Hospital
- Principal Investigator: Laura Whiteley, M.D., Rhode Island Hospital
- Study Director: Leandro Mena, M.D., University of Mississippi Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hiv
-
Duke UniversityGilead SciencesRecruitingHIV Prevention | HIV Pre-exposure Prophylaxis | HIV Prevention Program | HIV Prevention and Care | HIV Pre-exposure Prophylaxis UseUnited States
-
Federal University of São PauloGilead SciencesCompleted
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
University of Alabama at BirminghamNational Institute of Mental Health (NIMH)RecruitingPrEP | HIV | HIV Prevention | PrEP UptakeUnited States
-
Institute of HIV Research and Innovation Foundation...National Institutes of Health (NIH)RecruitingHIV Prevention | PrEP Adherence | HIV Related StigmaThailand
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH)RecruitingFeasibility | HIV Prevention | PrEP Uptake | Acceptability | HIV Self-testing | Male Partners of HIV-negative Postpartum WomenSouth Africa
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of PennsylvaniaNational Institute of Mental Health (NIMH); University of BotswanaRecruitingPregnancy | HIV | Post-partum | HIV Antiretroviral Therapy (ART) AdherenceBotswana
Clinical Trials on PrEP Mobile Messaging Intervention
-
Hilary L Surratt, PhDNational Institute on Drug Abuse (NIDA)Enrolling by invitationHIV PreventionUnited States
-
Georgetown UniversityCompleted
-
Medical College of WisconsinEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedPremature Birth | Decision Making | Resuscitation | Infant, Premature | Prenatal CareUnited States
-
Columbia UniversityRobert Wood Johnson FoundationCompletedPregnancy Related | Infant DevelopmentUnited States
-
The University of Hong KongFood and Health Bureau, Hong KongRecruiting
-
University of California, San FranciscoUniversity of California, Berkeley; Agency for Healthcare Research and Quality...CompletedDepression | Diabetes | Physical ActivityUnited States
-
Health Services Academy, Islamabad, PakistanCompletedOral Hygiene | Dental Plaque Induced GingivitisPakistan
-
Michigan State UniversityUniversity of MichiganActive, not recruiting
-
Boston UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedBreastfeeding | SUID | SIDSUnited States
-
Johns Hopkins UniversityWithdrawnUrinary Incontinence | Prostate Cancer | Erectile Dysfunction Following Radical ProstatectomyUnited States